What is new in pleural infections?
Abstract
The field of pleural medicine has seen significant advances in recent years, shaping both the current and future evaluation and treatment of pleural infection. Recent studies have demonstrated a continued rise in the prevalence of pleural infection and provide a more refined understanding of the risk factors associated with its occurrence. The increased use of point-of-care ultrasound and the identification of computed tomography markers have enhanced and expedited initial evaluation. Novel microbiological techniques are expanding our understanding of the diversity of causative pathogens and disease mechanisms, with potential implications for diagnostic strategies and antibiotic selection. Emerging studies are also exploring the feasibility of shorter courses of antibiotics. Meanwhile, novel blood and pleural fluid biomarkers are being increasingly studied for both diagnosis and prognostication. Furthermore, accumulating evidence on risk stratification is increasingly being published and used in clinical settings. The specific role, optimal sequence and patient selection for intrapleural enzyme therapy, surgery, and medical thoracoscopy is enabling a more personalised approach to treatment and may improve patient outcomes. These and other developments are discussed in this review, which presents a state-of-the-art overview of pleural infection management from the clinician's perspective, highlighting recent and anticipated advances.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.